SUIT-011: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
! Pathway control | ! Pathway control | ||
! Pathway to Q | ! Pathway to Q | ||
! Comment | |||
|- | |- | ||
Line 27: | Line 28: | ||
| [[N]] | | [[N]] | ||
| CI | | CI | ||
| ''See'' 2D. | |||
|- | |- | ||
Line 33: | Line 36: | ||
| [[N]] | | [[N]] | ||
| CI | | CI | ||
| GM and PM yield practically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM, since the fractions of the N-pathway is lower and of the S-pathway is higher with GM compared to PM. PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-linked (CI-linked) pathway. ''Compare'' [[SUIT targetRP1 NS]] and [[SUIT RP1]]. | |||
|- | |- | ||
| 3c | | 3c | ||
| [[GM]]( | | [[GM]](c) | ||
| [[N]] | | [[N]] | ||
| CI | | CI | ||
| Cytochrome ''c'' added immediately after the earliest ADP-activation step. Application of the cytochrome ''c'' test early in the protocol ensures comparability of all states in case of any effect of ''c'' ([[Gnaiger 2007 MitoPathways]]). | |||
|- | |- | ||
| | | 3S | ||
| [[GMS]](P) | | [[GMS]](P) | ||
| [[NS]] | | [[NS]] | ||
| CI&II | | CI&II | ||
| | |||
|- | |- | ||
Line 51: | Line 57: | ||
| [[NS]] | | [[NS]] | ||
| CI&II | | CI&II | ||
| The additive effect of N+S measured separately compared to the combined NS pathway cannot be evaluated in the same coupling state. With N<sub>''P''</sub>, NS<sub>''P''</sub>, NS<sub>''E''</sub>, and S<sub>''E''</sub>. If independent information is available on S<sub>''P''</sub> = S<sub>''E''</sub>, the additivity can be calculated for the OXPHOS state. | |||
|- | |- | ||
Line 57: | Line 64: | ||
| [[S]] | | [[S]] | ||
| CII | | CII | ||
| A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity. | |||
|- | |- | ||
Line 63: | Line 71: | ||
| ROX | | ROX | ||
| ROX | | ROX | ||
| ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the basis of ROX correction of mitochondrial respiration (mt). | |||
|} | |} |
Revision as of 09:51, 30 August 2016
Description
SUIT-catg: NS
Abbreviation: NS_1GM 2D 3c 4S 5U 6Rot 7Ama
Reference: MiPNet12.23 FibreRespiration
MitoPedia concepts:
SUIT protocol
- Subcatg: N+NS+S
- SUIT protocol pattern: diametral
- Mark names in DatLab: MiPNet12_23_FibreRespiration
- DatLab-Excel template: SUIT_MiPNet12.23_FibreRespiration.xlsx
Step | Respiratory state | Pathway control | Pathway to Q | Comment |
---|---|---|---|---|
1GM | GM(L) | N | CI | See 2D.
|
2D | GM(P) | N | CI | GM and PM yield practically identical fluxes in human skeletal muscle fibres. However, PM is the superior alternative to GM, since the fractions of the N-pathway is lower and of the S-pathway is higher with GM compared to PM. PM, therefore, yields a more sensitive assay for the diagnosis of injuries in the N-linked (CI-linked) pathway. Compare SUIT targetRP1 NS and SUIT RP1. |
3c | GM(c) | N | CI | Cytochrome c added immediately after the earliest ADP-activation step. Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c (Gnaiger 2007 MitoPathways). |
3S | GMS(P) | NS | CI&II | |
5U | GMS(E) | NS | CI&II | The additive effect of N+S measured separately compared to the combined NS pathway cannot be evaluated in the same coupling state. With NP, NSP, NSE, and SE. If independent information is available on SP = SE, the additivity can be calculated for the OXPHOS state. |
6Rot | S(E) | S | CII | A succinate concentration of >10 mM may be required for saturating SE capacity. |
10Ama | ROX | ROX | ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the basis of ROX correction of mitochondrial respiration (mt). |